In this study, we unveiled a novel role for NLRP4 within NSCLC TIME, acting as the catalyst to unlock an anti-tumor NLRP4-eco composed of NKomega and M1omega, much like identifying the driver mutation that underpins a particular cancer molecular subtype. Here, NLRP4 is linked to neoplasm.